PLAINVIEW, N.Y. (PRWEB)
November 19, 2020

The National Cancer Center is pleased to announce the launch of the Prostate Cancer Project to fund post-doctorate fellows pursuing promising and innovative research in prostate cancer. This project will be the National Cancer Center’s sixth research program focused on finding better diagnostic tools, better treatments and ultimately a cure for cancer.

The Prostate Cancer Project builds on the NCC’s success in providing financial support to researchers undertaking promising studies that seek to cure breast cancer, childhood leukemia, aggressive cancer and other childhood cancers. The NCC awards grants of $40,000 annually to eligible young scientists. If the grantee demonstrates good progress at the conclusion of the first year, he or she is eligible for an additional grant of $42,000 for a second year. The NCC has awarded more than $500,000 in grants this year.

“More than three million men in the U.S. are living with prostate cancer. Determining the most effective treatment plans for men at different stages of the disease proves to be one of the largest challenges, and is one reason we are so passionate about this project,” said Regina English, Executive Director, National Cancer Center.

Applications, which can be found here, will be considered through December 23, 2020; grantees will be notified on May 18, 2021.

For nearly 70 years, the NCC has been dedicated to providing financial support to research with the promise of conquering cancer. The NCC runs six cancer research programs: Aggressive Cancer Project; Fighting Childhood Leukemia; The Breast Cancer Project; Children’s Cancer Project; Prostate Cancer Project and the NCC Project. The organization also provides education on the prevention, diagnosis and treatment of cancer.

About National Cancer Center

National Cancer Center was founded by Dr. J. Ernest Ayre in 1953 as a non-profit organization committed to research and education about cancer. Dr. Ayre was a pioneer in refining and promoting the Pap test for women, a major factor in reducing deaths from cervical cancer. He was also one of the first researchers to recognize the enormous potential of Interferon for cancer treatment. NCC currently funds research at Duke University, Yale University, Dana-Farber Cancer Institute at Harvard University, the Salk Institute, Children’s Hospital of Philadelphia and other prominent universities and research institutes throughout the U.S.

Share article on social media or email: